Fridkin M - Search Results

1

Vanadate restores glucose 6-phosphate in diabetic rats: a mechanism to enhance glucose metabolism.

Sun Q, Sekar N, Goldwaser I, Gershonov E, Fridkin M, Shechter Y. Sun Q, et al. Among authors: fridkin m. Am J Physiol Endocrinol Metab. 2000 Aug;279(2):E403-10. doi: 10.1152/ajpendo.2000.279.2.E403. Am J Physiol Endocrinol Metab. 2000. PMID: 10913041 Free article.

2

L-Glutamic acid gamma-monohydroxamate. A potentiator of vanadium-evoked glucose metabolism in vitro and in vivo.

Goldwaser I, Li J, Gershonov E, Armoni M, Karnieli E, Fridkin M, Shechter Y. Goldwaser I, et al. Among authors: fridkin m. J Biol Chem. 1999 Sep 10;274(37):26617-24. doi: 10.1074/jbc.274.37.26617. J Biol Chem. 1999. PMID: 10473627 Free article.

3

Insulin-like effects of vanadium: basic and clinical implications.

Goldwaser I, Gefel D, Gershonov E, Fridkin M, Shechter Y. Goldwaser I, et al. Among authors: fridkin m. J Inorg Biochem. 2000 May 30;80(1-2):21-5. doi: 10.1016/s0162-0134(00)00035-0. J Inorg Biochem. 2000. PMID: 10885459 Review.

4

New concept for long-acting insulin: spontaneous conversion of an inactive modified insulin to the active hormone in circulation: 9-fluorenylmethoxycarbonyl derivative of insulin.

Gershonov E, Shechter Y, Fridkin M. Gershonov E, et al. Among authors: fridkin m. Diabetes. 1999 Jul;48(7):1437-42. doi: 10.2337/diabetes.48.7.1437. Diabetes. 1999. PMID: 10389850

5

A novel approach for a water-soluble long-acting insulin prodrug: design, preparation, and analysis of [(2-sulfo)-9-fluorenylmethoxycarbonyl](3)-insulin.

Gershonov E, Goldwaser I, Fridkin M, Shechter Y. Gershonov E, et al. Among authors: fridkin m. J Med Chem. 2000 Jun 29;43(13):2530-7. doi: 10.1021/jm990533m. J Med Chem. 2000. PMID: 10891112

6

Organic vanadium chelators potentiate vanadium-evoked glucose metabolism in vitro and in vivo: establishing criteria for optimal chelators.

Goldwaser I, Qian S, Gershonov E, Fridkin M, Shechter Y. Goldwaser I, et al. Among authors: fridkin m. Mol Pharmacol. 2000 Oct;58(4):738-46. doi: 10.1124/mol.58.4.738. Mol Pharmacol. 2000. PMID: 10999943

7

Suspensions of pro-drug insulin greatly prolong normoglycemic patterns in diabetic rats.

Shechter Y, Tsubery H, Fridkin M. Shechter Y, et al. Among authors: fridkin m. Biochem Biophys Res Commun. 2003 Jul 25;307(2):315-21. doi: 10.1016/s0006-291x(03)01200-2. Biochem Biophys Res Commun. 2003. PMID: 12859957

8

[2-Sulfo-9-fluorenylmethoxycarbonyl]3-exendin-4-a long-acting glucose-lowering prodrug.

Shechter Y, Tsubery H, Fridkin M. Shechter Y, et al. Among authors: fridkin m. Biochem Biophys Res Commun. 2003 May 30;305(2):386-91. doi: 10.1016/s0006-291x(03)00715-0. Biochem Biophys Res Commun. 2003. PMID: 12745087

9

Albumin-insulin conjugate releasing insulin slowly under physiological conditions: a new concept for long-acting insulin.

Shechter Y, Mironchik M, Rubinraut S, Saul A, Tsubery H, Fridkin M. Shechter Y, et al. Among authors: fridkin m. Bioconjug Chem. 2005 Jul-Aug;16(4):913-20. doi: 10.1021/bc050055w. Bioconjug Chem. 2005. PMID: 16029032

10

Reversible pegylation of insulin facilitates its prolonged action in vivo.

Shechter Y, Mironchik M, Rubinraut S, Tsubery H, Sasson K, Marcus Y, Fridkin M. Shechter Y, et al. Among authors: fridkin m. Eur J Pharm Biopharm. 2008 Sep;70(1):19-28. doi: 10.1016/j.ejpb.2008.03.018. Epub 2008 Apr 7. Eur J Pharm Biopharm. 2008. PMID: 18495444

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

335 results

Search Page

Filters